Newsroom

March 2018

• Press release Mar 23, 2018

  Phase III data in The Lancet show Novartis siponimod significantly improves outcomes in patients with secondary progressive MS

  EXPAND shows oral siponimod (BAF312) is the first potential therapy to meaningfully delay disability progression in typical secondary progressive MS (SPMS) patients   Results demonstrate…
• Press release Mar 22, 2018

  Novartis drug Tasigna® approved by FDA to treat children with rare form of leukemia

  Tasigna® (nilotinib) approved for pediatric patients with newly diagnosed Ph+ CML-CP and children with Ph+ CML-CP resistant or intolerant to prior TKI therapy New indication approved under FDA…
• 
  Story Mar 20, 2018 Discovery

  Building “boot camps” for immune cells near tumors

  Bioengineers, immunologists and clinicians collaborate to explore a new approach to fighting cancer.

• Press release Mar 20, 2018

  Novartis teams up with Harvard to develop next generation biomaterial systems to deliver immunotherapies

  Collaboration and licensing agreement combine Harvard's expertise in tumor biology and materials science with Novartis' diverse immuno-oncology pipeline  Teams will explore the development…
• Featured News Mar 19, 2018

  Novartis Foundation joins Global Partnership for Zero Leprosy

  Leprosy is an ancient disease that currently infects more than 200 000 people each year. For more than three decades, Novartis and the Novartis Foundation has been working to reduce the incidence of leprosy, and the Novartis Foundation recently helped establish the Global Partnership for Zero Leprosy in an effort to eliminate the disease.

• Press release Mar 13, 2018

  AveXis Enters into Licensing Agreement with Genethon

  Includes exclusive worldwide rights to AAV9-SMN product and route of administration CHICAGO and ÉVRY, France, March 13, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS) and Genethon today…
• Ad hoc release Mar 12, 2018

  Novartis announces changes to the Executive Committee to support strategic priorities

  Bertrand Bodson, Chief Digital Officer, appointed to the Executive Committee of Novartis (ECN) Steffen Lang, Global Head Novartis Technical Operations, appointed to the ECN Shannon Klinger…
• Ad hoc release Mar 12, 2018

  Novartis kündigt Veränderungen in der Geschäftsleitung zur Unterstützung strategischer Prioritäten an

  Bertrand Bodson, Chief Digital Officer, wird in die Geschäftsleitung von Novartis berufen Steffen Lang, Global Head Novartis Technical Operations, wird in die Geschäftsleitung von Novartis berufen…
• Ad hoc release Mar 12, 2018

  Novartis annonce des changements au sein de son Comité de direction afin de soutenir ses priorités stratégiques

  Bertrand Bodson, Chief Digital Officer, est nommé au Comité de direction de Novartis (Executive Committee of Novartis, ECN) Steffen Lang, Global Head Novartis Technical Operations, est nommé à l'ECN…
• Press release Mar 07, 2018

  Novartis expands alliance with Science 37 to advance virtual clinical trials program

  Novartis and Science 37 commit to launch up to 10 trials with increasing decentralization over three years, scaling to "site-less" model Agreement builds on our long-standing investment in and…
• Press release Mar 06, 2018

  Novartis' Xolair® recommended in new global chronic urticaria guideline

  Xolair® (omalizumab), indicated as add-on therapy for the treatment of chronic spontaneous urticaria (CSU)[1], is the only therapy recommended by the guideline for patients unresponsive to…
• 
  Story Mar 02, 2018 Access to Healthcare

  Positive gains are needed to accelerate change for women with lung disease

  COPD receives low attention as a women’s health issue. It’s time to change that.